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Objective: Several biologic mediators and genetic predisposing factors may contribute to the development of peripheral
arterial disease (PAD). The eNOS gene, encoding for endothelial nitric oxide synthase, has been proposed as a candidate
gene in the predisposition to the disease. In this study, we evaluated the role of eNOS-786T>C, -894G>T and 4a/4b
polymorphisms as markers of PAD per se and in the presence of the ACE D allele in patients previously investigated.
Methods: We analyzed 281 consecutive patients (220 men, 61 women; median age, 72 years) with PAD and 562 healthy
controls, comparable for sex and age.
Results: eNOS-786C, but not -894T and 4a, allele frequency was significantly higher in PAD patients than in controls
(P .03). An association with the predisposition to PADwas found for the eNOS-786C allele (odds ratio [OR], 1.52; 95%
confidence interval [CI], 1.11-2.09; P .009) and the eNOS -786C/4a haplotype (OR, 1.41; 95% CI, 1.02-1.94, P .04)
at univariate analysis but not after adjustment for traditional risk factors. When smoking habit was considered, we
observed that eNOS-786C/4a haplotype, but not the eNOS-786C allele, influenced PAD predisposition after adjustment
for traditional risk factors in smokers (OR, 2.71; 95% CI, 1.38-5.30; P  .004). The eNOS-786C and eNOS-786C/4a
haplotype did not modify the susceptibility to PAD in patients carrying the ACE D allele. Nevertheless, the presence of
the eNOS-786C/4a haplotype increased PAD predisposition in smokers also carrying ACE D allele (OR, 2.71 to 3.79;
P > .05 for interaction).
Conclusions: This study demonstrated an association between eNOS and ACE genes in increasing PAD susceptibility in
smokers, thus providing evidence for a gene-environment interaction in modulating predisposition to the disease.
(J Vasc Surg 2010;52:97-102.)Peripheral arterial disease (PAD), a common manifes-
tation of systemic atherosclerosis, represents one of the
different localizations of the atherosclerotic process. PAD is
associated with an increased risk of cardiovascular events
mainly related to the coexistence of coronary artery disease
(CAD) and cerebrovascular disease.1 Apart from traditional
cardiovascular risk factors such as hypertension, smoking
habit, dyslipidemia, and diabetes, several novel biologic
mediators and genetic predisposing factors appear to be
relevant in determining the atherogenic process.1
Endothelial dysfunction is a key step in the initiation
and progression of atherogenesis, and nitric oxide (NO) is
able tomodulate most of the steps that are important in this
process.2 NO contributes to vascular tone regulation, inhi-
bition of platelet aggregation, leukocyte adhesion to vascu-
lar endothelium, and inhibition of smooth muscle cell
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vent the development of the atherosclerotic plaque.2
NO is synthesized from L-arginine by at least three
isoforms of NO synthase (NOS): inducible NOS, neuronal
NOS, and endothelial (eNOS).3 Experimental data con-
cerning the role of eNOS responsible for NO synthesis in a
eNOS knockout mice model demonstrated that, in the
absence of eNOS, luminal remodeling is impaired and
vessel wall thickness is doubled. These data suggested that
endothelial-derived NO, in addition to its role as a vasodi-
lator, might be involved in controlling vessel wall geome-
try.4
NO availability may be genetically determined, and
there is documented evidence that a reduction in NO
synthesis, associated with eNOS gene polymorphisms, is
linked to endothelial dysfunction.5 The eNOS gene (7q35-
q36) exhibits several polymorphisms, some of which appear
to be related to the variability in NO plasma levels. A
substitution of guanine to thymine at nucleotide 894 in
exon 7 of the eNOS gene (894GT polymorphism) is
associated with reduced basal NO production;6 the rare C
allele of the -786TC polymorphism in the 5=-flanking
region of the gene results in a significant reduction in eNOS
promoter activity;7 and, finally, a 27-base pair (bp) variable
tandem repeat polymorphism in intron 4 (also called eNOS
4a4b) has been associated with variations in NO, nitrite,
and nitrate plasma levels.8 Recently, it has demonstrated a
functional role for the eNOS 4a4b polymorphism: individ-
uals carrying the 4a4a genotype have lower NO-producing
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higher eNOS messenger RNA levels were observed.9
We previously demonstrated a role for the eNOS gene
in influencing atherosclerosis by modulating the predispo-
sition to carotid atherosclerosis,10 abdominal aortic aneu-
rysm (AAA),11 and CAD.12 To the best of our knowledge,
few data are available concerning the influence of the eNOS
gene in modulating the susceptibility to PAD.13
We recently showed that the I/D polymorphism in the
gene encoding for angiotensin-converting enzyme (ACE)
is involved in modulating the predisposition to PAD.1 To
date, polymorphisms in genes encoding for renin angioten-
sin system components, such as the ACE gene, might
contribute to increased angiotensin II levels, which may be
crucial in the development of the atherosclerotic process. In
particular, we recently documented14 that the ACE D/-
240T haplotype modulates PAD susceptibility, apart from
other atherosclerotic localizations and traditional cardio-
vascular risk factors. ACE may affect the atherosclerotic
process through bradykinin degradation and NO release
reduction, thus possibly inducing PAD phenotype. A re-
duced NO availability, which may be also genetically deter-
mined, promotes endothelial dysfunction, one of the earli-
est processes in the development of atherosclerosis.15
Owing to the polygenic nature of PAD, in the present
study, we investigated the contribution of the ACE and
eNOS genes as markers of the atherosclerotic process lead-
ing to PAD. Therefore, we analyzed eNOS-786TC,
-894GT, and 4a/4b polymorphisms, which are able to
modulate NO availability, as predisposing factors to PAD
per se and in the presence of the ACE D allele, which
previously was demonstrated to influence PAD susceptibil-
ity.14
MATERIALS AND METHODS
All participants in this study gave informed consent.
The study was complied with the Declaration of Helsinki
and was approved by the local ethics committee.
Study population. The study population consisted of
281 patients previously investigated14 with symptoms or
signs suggestive for the presence of PAD, who were re-
ferred to the Unit of Vascular Surgery of the University of
Florence, AOU-Careggi, to be evaluated for possible sur-
gical intervention. This was a retrospective case-control
association study. PAD was diagnosed when patients had
typical symptoms of intermittent claudication, such as
cramping pain of the calves or buttocks during exercise and
an ankle-brachial index (ABI) of 0.90 at rest, calculated
according to the recommendations of the American Heart
Association.16
All patients were also evaluated for atherosclerotic dis-
ease at other locations. In particular, a cardiologic evalua-
tion including electrocardiogram and echocardiogram was
performed in all patients. In patients with symptoms poten-
tially related to ischemic heart disease, additional studies
were performed (echocardiogram with drug-induced stress
testing, myocardial scintigraphy, and/or coronary angiog-
raphy) according to American College of Cardiology/American Heart Association guidelines.17 Carotid artery
duplex scanning with color-coded echo-flow imaging was
conducted according to North American Symptomatic Ca-
rotid Endarterectomy Trial criteria.18 Rutherford catego-
ries were assigned as follows: class 2, moderate claudica-
tion; class 3, severe claudication; class 4, rest pain; and class
5-6, ulcers or gangrene.19
The patients were compared with a control group of
562 age- and sex-matched individuals without symptom-
atic PAD recruited from the staff of the University of
Florence and the hospital or those who were partners or
friends of patients. Expert physicians performed, in the
frame of a physical examination, a detailed interview ad-
dressed to personal and familial history to identify disease-
free controls and to exclude individuals who were thought
to have any form of vascular disease (Appendix, online
only).
Participants were considered to have hypertension if
they had been diagnosed as hypertensives (systolic blood
pressure 140 mm Hg, diastolic blood pressure 90 mm
Hg) according to the guidelines of European Society of
Hypertension/European Society of Cardiology20 or were
taking antihypertensive drugs. Dyslipidemia was defined as
total cholesterol levels 190 mg/dL, low-density lipopro-
tein 115 mg/dL, high-density lipoprotein 46 mg/dL
in women and 40 mg/dL in men, and triglyceride levels
150 mg/dL, according to the third report of the Na-
tional Cholesterol Education Program (NCEP).21 Diabe-
tes was defined in agreement with the American Diabetes
Association.22 Smokers were defined as current or recent
(ex-smokers who stopped 5 years previously). A positive
family history was defined as the presence of at least one
first-degree relative who had developed cardiovascular dis-
ease before the age of 55 years for men and 65 years for
women.
Detection of ACE and eNOS polymorphisms.
Genomic DNAwas isolated from whole blood by using the
FlexiGeneDNA kit (QIAGEN, Germany), which permits
DNA purification through precipitation after isopropanol
addition and recovery by centrifugation. RecoveredDNA is
washed in 70% ethanol, dried, and resuspended in a hydra-
tion buffer.
The ACE I/D polymorphism has been evaluated by
polymerase chain reaction (PCR) and electrophoresis on
agarose gel to permit genotyping discrimination (DD, ID,
and II genotypes), as previously described.23
The eNOS-786TC (rs2070744) and -894GT
(rs1799983) polymorphisms were evaluated through elec-
tronic microchip technology (NanoChip Molecular Biology
Workstation; 10  10 array NanoChip cartridge; Nanogen,
SanDiego,Calif), aDNAmicroarray technology based on the
application of an electric field that allows the rapid deposition
of biotinylated PCR products, derived from the amplification
of the genomic sequence containing each polymorphism
through PCR reaction, on a streptavidin-coated array. The
PCR products hybridize to fluorescent-specific probes to per-
mit genotype discrimination.24
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PCR reaction as previously described.12
Statistical analysis. Statistical analysis was performed
by using SPSS 11.5 software (SPSS Inc, Chicago, Ill).
Continuous variables were expressed as median (range),
and the nonparametric Mann-Whitney test for unpaired
data was used for comparison between single groups, as
appropriate. The 2 test was used to test for deviation of
genotype distribution from Hardy-Weinberg equilibrium.
The 2 test was also used to evaluate the differences in
genotype distribution and allele frequency and in the prev-
alence of traditional risk factors between patients and con-
trols.
During genotyping of the eNOS 4a/4b polymorphism
in PAD patients, we found the presence of a rarer d allele
previously described in acute coronary syndrome pa-
tients.25 Patients carrying this allele were excluded to avoid
confounding effects on statistical analysis. The association
between eNOS polymorphisms and PAD was assessed by
using logistic regression analysis under a dominant genetic
model of inheritance that compares individuals with one or
more polymorphic alleles with a baseline group with no
polymorphic alleles (eg, eNOS-786CC  -786TC vs -786TT).
Variables that showed a statistically significant association
with PAD susceptibility at univariate analysis were intro-
duced in a multivariate model. The odds ratio (OR) with
95% confidence interval (CI) was determined. A value of
P  .05 was considered to indicate statistical significance.
Only one study has investigated the prevalence of eNOS
polymorphisms in white patients13; therefore, in a priori
sample size calculation, we referred to our previous obser-
vations in white patients with atherosclerosis.10-12 Accord-
ingly, a sample size of at least 250 individuals in each group
Table I. Demographic and clinical characteristics of the
study populations
Variable
Patients
(n 281)
Controls
(n  562) P value
Age, ya 72 (30-93) 71 (24-95) .4
Males 220 (78) 422 (75.0) .3
Hypertension 167 (59.4) 112 (19.9) .0001
Diabetes 47 (16.7) 28 (5.0) .0001
Dyslipidemia 135 (48) 107 (19.0) .0001
Smokers (current or
recent)b 176 (62.6) 118 (21.0) .0001
Family history 56 (19.9) 34 (6.0) .0001
Coronary artery disease 70 (24.9) . . . . . .
Abdominal aortic
aneurysm 34 (12.1) . . . . . .
Carotid atherosclerosis 28 (10.0) . . . . . .
Rutherford category
2 28 (10.0) . . . . . .
3 188 (66.9) . . . . . .
4 48 (17.1) . . . . . .
5-6 17 (6.0) . . . . . .
aAge is presented as median (range); all other data are number (%).
bEx-smokers who stopped 5 years previously.was deemed sufficient to prove or exclude an associationbetween eNOS polymorphisms and PAD with a statistical
power () of 80% and significance value of 0.05 ().
RESULTS
Demographic and clinical characteristics of the study
population are described in Table I. The prevalence of
traditional cardiovascular risk factors was significantly
higher in patients than in controls (Table I), and 91 of 281
PAD patients had at least one other atherosclerotic local-
ization (CAD, carotid atherosclerosis) and AAA.
No deviation from the expected genotype proportion
predicted by the Hardy-Weinberg equilibrium was ob-
served for the polymorphisms analyzed (Table II). Con-
cerning the eNOS 4a4b polymorphism, we excluded from
the analysis two patients carrying the previously identified
rare d allele25 to avoid confounding effects.
A significant difference in genotype distribution and
allele frequency between PAD patients and controls was
observed for eNOS-786TC but not for -894GT and the
4a/4b polymorphism (Table II).
We analyzed genotype distribution and allele frequency
for all eNOS polymorphisms investigated, according to the
presence or absence of at least any other atherosclerotic
localization. We observed no difference between the two
groups (P  .05).
At univariate logistic regression analysis, the eNOS-
786C allele was significantly associated with PAD; never-
theless, the -786C allele did not influence the susceptibility
to PAD after an adjustment for age, sex, and traditional risk
factors (Table III). No significant association was observed
Table II. Genotype distribution and allele frequencies of
eNOS gene polymorphisms of the study populationsa
Genotype Allele
Patients
(n 281)
No. (%)
Controls
(n  562)
No. (%) P value
eNOS
	786TT 74 (26.3) 198 (35.2)
	786TC 153 (54.4) 269 (47.9)
	786CC 54 (19.2) 95 (16.9) .03
	786C 0.46 0.41 .03
894GG 120 (42.7) 228 (40.6)
894GT 134 (47.7) 259 (46.1)
894TT 27 (9.6) 75 (13.3) .3
894T 0.33 0.36 .2
4b/4ba 188 (66.9) 388 (69.0)
4a/4b 81 (28.8) 152 (27.0)
4a/4a 10 (3.6) 22 (3.9) .8
4a 0.18 0.17 .7
eNOS, Endothelial nitric oxide synthase.
-786TT: homozygotes for T allele; -786TC: heterozygotes for T and C
alleles; -786CC: homozygotes for the rare allele C.
894GG: homozygotes for G allele; 894GT: heterozygotes forG and T alleles;
894TT: homozygotes for the rare allele T.
4b/4b: homozygotes for 4b allele; 4a/4b: heterozygotes for 4a and 4b alleles;
4a/4a: homozygotes for the rare allele 4a.
aTwo patients heterozygous for the rare d allele were not included in the
analysis.in the other two polymorphisms analyzed (Table III). In
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observed a significant association with PAD susceptibility at
univariate but not at multivariate analysis (Table III).
No significant difference was observed in genotype
distribution for the polymorphisms analyzed, according to
Rutherford categories (data not shown).
Because experimental data demonstrated that the eNOS-
786C/4a haplotype is differently able to modulate eNOS gene
expression in the presence or absence of smoking habit,26 we
analyzed the role of the eNOS gene inmodulating PAD suscep-
tibility separately in smokers and in nonsmokers. In smokers, but
not in nonsmokers, we observed that the eNOS-786C allele, but
Table III. Univariate and multivariate analyses for eNOS
Variable
Age
Sex
Hypertension
Smoking habit
Diabetes
Dyslipidemia
eNOS -786C
eNOS 894T
eNOS 4a
eNOS -786C /4a
eNOS -786C and 4a variants in patients carrying ACE D allele
ACE D
ACE D/eNOS-786C
ACE D/eNOS-786C/ 4a
ACE, Angiotensin-converting enzyme; eNOS, endothelial nitric oxide synth
aAdjusted for age, sex, and traditional cardiovascular risk factors.
Table IV. Univariate and multivariate analyses for eNOS a
arterial disease according to smoking habit
Analysis
Univariate analysis
eNOS –786C
eNOS 894T
eNOS 4a
eNOS -786C/4a
Multivariate analysisa
eNOS -786C
eNOS -786C/4a
eNOS -786C and 4a variants in individuals carrying ACE D allele
Univariate analysis
ACE D
ACE D/eNOS -786C
ACE D/eNOS -786C/ 4a
Multivariate analysisa
ACE D
ACE D/eNOS -786C
ACE D/eNOS -786C/4a
ACE, Angiotensin-converting enzyme; eNOS, endothelial nitric oxide synth
aAdjusted for age, sex, and traditional cardiovascular risk factors.not -894T and 4a, was associatedwith PADat univariate analysis(Table IV); however, this association was not confirmed after
adjustment for age, sex, and the other risk factors (Table IV). In
smokers, the contemporary presence of the eNOS-786C and 4a
alleles significantlymodulated the predisposition toPADat both
univariate andmultivariate analysis (Table IV).
Because we had previously demonstrated in the same
patients14 that the ACE D allele influenced the predisposi-
tion to PAD, in the present study, we searched for a role of
eNOS alleles in modulating PAD susceptibility in patients
also carrying theACED allele. In these patients, neither the
eNOS-786C allele nor the eNOS-786C/4a haplotype mod-
ified the susceptibility to PAD (Table III). Nevertheless,
CE gene polymorphisms and susceptibility to PAD
Univariate analysis Multivariate analysisa
R (95% CI) P value OR (95% CI) P value
1 (0.99-1.02) .06 . . . . . .
0 (0.56-1.13) .2 . . . . . .
7 (4.56-8.63) .0001 . . . . . .
2 (4.89-9.23) .0001 . . . . . .
5 (2.41-6.47) .0001 . . . . . .
3 (2.43-4.56) .0001 . . . . . .
2 (1.11-2.09) .009 0.99 (0.65-1.52) .9
2 (0.68-1.22) .5 . . . . . .
0 (0.81-1.50) .5 . . . . . .
1 (1.02-1.94) .04 1.20 (0.81-1.82) .4
0 (1.29-2.81) .001 1.90 (1.16-3.10) .01
0 (1.11-2.02) .009 1.30 (0.89-1.91) .2
0 (0.99-1.98) .05 . . . . . .
CE gene polymorphisms and susceptibility to peripheral
Smokers (n  176) Non smokers (n  105)
OR (95% CI) P value OR (95% CI) P value
.84 (1.10-3.08) .02 1.23 (0.77-1.97) .4
.78 (0.48-1.27) .3 0.79 (0.51-1.22) .3
.40 (0.84-2.33) .2 0.95 (0.59-1.52) .8
.14 (1.22-3.76) .008 1.13 (0.69-1.84) .6
.54 (0.80-2.98) .2 . . . . . .
.71 (1.38-5.30) .004 . . . . . .
. . .
.84 (1.49-5.43) .002 1.22 (0.71-2.11) 0.5
.06 (1.2-3.43) .006 1.01 (0.65-1.58) 0.9
.45 (1.27-4.71) .007 1.02 (0.60-1.74) 0.9
.82 (1.33-5.99) .007 . . . . . .
.26 (1.25-4.09) .007 . . . . . .
.79 (1.78-8.06) .001 . . . . . .and A
O
1.0
0.8
6.2
6.7
3.9
3.3
1.5
0.9
1.1
1.4
1.9
1.5
1.4
ase.nd A
1
0
1
2
1
2
2
2
2
2
2
3
ase.the presence of the eNOS-786C/4a haplotype increased
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 1 Sticchi et al 101PAD predisposition in smokers also carrying the ACE D
allele (OR, 2.71-3.79; P  .05 for interaction; Table IV).
DISCUSSION
Owing to the multifactorial nature of PAD, in which
genetic components and environmental factors interact in
determining its pathogenesis, in the present study, we
evaluated the influence of genetic variants in another can-
didate gene, such as eNOS, as predisposing factors to PAD,
and we provided the novel finding of the effect of eNOS in
increasing the predisposition to the disease in smokers. This
effect was evident also in those smokers carrying theACED
allele. We provided further evidence of a combined effect of
two candidate genes, ACE and eNOS, with the known
effect on endothelial dysfunction,27 in conferring a signifi-
cant risk of PAD developing in smokers. Therefore, our
findings contribute to highlight a gene–environment inter-
action that is able to modulate PAD predisposition.
We recently demonstrated a role for the ACE gene in
predisposing to PAD.14 The activity of the NO pathway is
reduced through ACE-induced bradykinin degradation,27
thus contributing to endothelial dysfunction. Data from
previous reports suggest that eNOS-derived NO acts as an
antiatherogenic molecule,2 and a reduced endogenous NO
synthesis facilitates the progression of atherosclerosis.2 A
genetically determined reduced NO availability contributes
to promote endothelial dysfunction, which reflects a spe-
cific atherogenic vascular milieu.
Established cardiovascular risk factors, such as smok-
ing, can cause endothelial damage severe enough to be
followed by atherosclerotic or thrombotic changes.28
Therefore, environmental factors such as smoking and the
genetic predisposition to endothelial dysfunction may in-
teract in affecting the atherosclerotic process.
Functional polymorphisms in the eNOS gene modulate
NO availability. Data from an experimental study demon-
strated a cis-acting role of the eNOS 4a allele on the
promoter functional activity, therefore, the 4a and -786C
variants cooperate in regulating transcription efficiency in a
haplotype-specific fashion.26 Moreover, the effect of the
-786C/4a haplotype in regulating eNOS gene expression is
further modified by cigarette smoking.26 As expected, we
found that a high percentage of PAD patients were smokers
(63%). On the basis of the experimental data fromWang et
al,6 we investigated the relationship between the eNOS-
786/4a haplotype and smoking and demonstrated an inter-
action affecting PAD susceptibility.
The role of the eNOS gene in modulating PAD suscep-
tibility has been poorly investigated. The Edinburgh artery
study,13 which analyzed the eNOS 4a/4b polymorphism,
did not demonstrate its role as a susceptibility factor to
PAD. Our results on the influence of this polymorphism in
a larger white population are in keeping with those from the
Edinburgh artery study.13
We previously demonstrated an association between
the eNOS gene and other atherosclerotic localizations, such
as CAD, carotid atherosclerosis, and AAAs.10-12 The weak
association between the eNOS gene and PAD, not con-firmed after adjustment for traditional risk factors, may be
related to the different percentage of cardiovascular risk
factors observed in the present study compared with those
observed in the different populations that have been inves-
tigated.10-12
This study has some limitations. The main limitation
was that we were not able to perform a Doppler examina-
tion with ABI measurement or diagnostic procedures to
evaluate asymptomatic atherosclerotic lesions in controls. A
percentage of individuals with PAD are clinically asymp-
tomatic, thus the possibility that our control group was
disease-free cannot be excluded.
Our study also lacked of measurements of nitrite/
nitrate (NOx) levels, which might have allowed us to
evaluate NO production andmight have contributed to the
overall interpretation of data.
CONCLUSIONS
This study showed an association between the eNOS
andACE genes and PAD in smokers and provides evidence
of a gene-environment interaction that modulates PAD
predisposition. Nevertheless, the lack of ABImeasurements
and our ability to exclude asymptomatic PAD in controls
might dim our results. Actually, the moderate occurrence
of asymptomatic PAD in individuals aged70 years might
mask the true effect of a genetic predisposition. On the
other hand, we observed the influence of the eNOS gene on
PAD predisposition only in smokers, whose percentage was
threefold higher in the patient group than in controls. To
date, the Framingham study documented that the risk of
PAD is twice as high in smokers as in nonsmokers.29 These
data might permit a hypothesis that the weight of smoking
in determining the atherosclerotic process was relevant
independently of the presence of potential asymptomatic
forms. Moreover, the combined effect of smoking and
genetically determined reduced NO availability might fur-
ther contribute in promoting the endothelial dysfunction
relevant in atherosclerosis, thus dimming potential con-
founding effects related to the presence of asymptomatic
forms.
Finally, the combined information from more genetic
variants may permit the identification of individuals at high
risk of developing a complex disorder; in particular, as
concerns PAD, this information may be useful to identify
those individuals among smokers at even higher risk to
develop the disease. Nevertheless, further studies per-
formed on larger samples are needed to support our in-
triguing finding. Pharmacologic strategies, such as supple-
mentation of the substrate for NO synthesis, L-arginine,
and NO donors, may offer a better control of endothelial
dysfunction, in particular, in smokers.
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DETAILED INTERVIEW FORM
ID number . . . . . . . . . .
Age . . . . . . . . .
Gender . . . . . . . . .
Family history (cardiovascular disease in first-degree rela-
tives: males: 55 yrs, females: 65 yrs)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Risk factors for cardiovascular disease:
Weight (Kg): . . . . . . . . . .
Height (m): . . . . . . . . . .
BMI: (kg/m2): . . . . . . . . . .
Physical activity: Yes . . . . . . . . . . No . . . . . . . . . .
Grade of physical activity:Light . . . . . . . . . .
Moderate. . . . . . . . . .
Intense . . . . . . . . . .
Smoking Habit:
No: . . . . . . . . . .
Yes: . . . . . . . . . . Current: . . . . . . . Ex-smoker: . . . .
Blood pressure: SBP (mm Hg): . . . . DBP (mm Hg): . . . .
Hypertension: Yes . . . . . . . . . . No . . . . . . . . . .
Therapy: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total cholesterol: . . . . . . . . . . HDL-C: . . . . . . . . . .
LDL-C: . . . . . . . . . Triglycerides: . . . . . . . . . .
Dyslipidemia: Yes . . . . . . . . . . No . . . . . . . . . .
Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diabetes: Yes. . .. . .. . .. . .. . .No. . .. . .. . .. . .. . .
Therapy. . .. . .. . .. . .. . .. . .. . .. . .. . .. . ..
Previous CAD: Yes . . . . . . No . . . . . . . when . . . . . . . . .
Previous stroke: Yes . . . . . . No . . . . . . . . when . . . . . .
Previous AAA: Yes. . . . . . . No . . . . . . . . when . . . . . . .
Carotid atherosclerosis: Yes . . . . . . . . . . No . . . . . . . . . .
Symptomatic PAD: Yes . . . . . . . . . . No . . . . . . .
